📰 Stable Dose News

Stable Dose News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Stable Dose. Real-time updates on events, politics, business and more.

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

March 13, 2023

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...

Mississippi River United States New Orleans Hidradenitis Suppurativa Celine Goldberger Boehringer Ingelheim

Source: prnewswire.com

RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

March 16, 2022

In clinical trials, RINVOQ (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 521-4 A greater...

United States Thomas Hudson Ann Gastroenterol Drug Administration Exchange Commission Abbvie Inc

Source: prnewswire.com

RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

March 16, 2022

In clinical trials, RINVOQ (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 521-4 A greater...

United States Thomas Hudson Ann Gastroenterol Drug Administration Exchange Commission Abbvie Inc

Source: prnewswire.com

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

January 14, 2022

NORTH CHICAGO, Ill., Jan. 14, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RI...

United States New York Dermatol Clin Thomas Hudson Emma Guttman Yassky National Eczema Association

Source: businessinsider.com

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

January 14, 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of...

United States New York Dermatol Clin Thomas Hudson Emma Guttman Yassky National Eczema Association

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

January 14, 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of...

United States New York Dermatol Clin Thomas Hudson Emma Guttman Yassky National Eczema Association

Source: prnewswire.com

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

June 2, 2021

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe...

United States Roym Fleischmann Mudra Kapoor European Commission Arthritis Care Research World Health Organization

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Stable Dose News Today

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

RINVOQ&#xAE; (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

RINVOQ&#xAE; (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

U.S. FDA Approves RINVOQ&#xAE; (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

U.S. FDA Approves RINVOQ&#xAE; (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

Stay Updated with Latest News

U.S. FDA Approves RINVOQ&#xAE; (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ&#xAE; (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

Explore More Categories

RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress